Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

59

Participants

Timeline

Start Date

November 1, 2012

Primary Completion Date

August 8, 2017

Study Completion Date

August 8, 2017

Conditions
Clear Cell Renal Cell CarcinomaRecurrent Renal Cell CarcinomaStage IV Renal Cell CancerType 1 Papillary Renal Cell CarcinomaType 2 Papillary Renal Cell Carcinoma
Interventions
BIOLOGICAL

Anti-Endoglin Chimeric Monoclonal Antibody TRC105

Given IV

BIOLOGICAL

Bevacizumab

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

Trial Locations (30)

100

National Taiwan University Hospital, Taipei

2050

Royal Prince Alfred Hospital, Camperdown

15232

University of Pittsburgh Cancer Institute (UPCI), Pittsburgh

21201

University of Maryland/Greenebaum Cancer Center, Baltimore

23298

Virginia Commonwealth University/Massey Cancer Center, Richmond

33136

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

33612

Moffitt Cancer Center, Tampa

37232

Vanderbilt University/Ingram Cancer Center, Nashville

46804

Fort Wayne Medical Oncology and Hematology Inc - Jefferson Boulevard, Fort Wayne

46845

Fort Wayne Medical Oncology and Hematology Inc-Parkview, Fort Wayne

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

48201

Wayne State University/Karmanos Cancer Institute, Detroit

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

55416

Metro Minnesota Community Oncology Research Consortium, Saint Louis Park

55905

Mayo Clinic, Rochester

60026

NorthShore University HealthSystem-Glenbrook Hospital, Glenview

60201

NorthShore University HealthSystem-Evanston Hospital, Evanston

60426

Ingalls Memorial Hospital, Harvey

60637

University of Chicago Comprehensive Cancer Center, Chicago

62526

Decatur Memorial Hospital, Decatur

63110

Washington University School of Medicine, St Louis

77030

M D Anderson Cancer Center, Houston

80045

University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora

90033

USC / Norris Comprehensive Cancer Center, Los Angeles

91010

City of Hope Comprehensive Cancer Center, Duarte

91030

City of Hope South Pasadena, South Pasadena

95817

University of California Davis Comprehensive Cancer Center, Sacramento

80217-3364

University of Colorado, Denver

08903

Rutgers Cancer Institute of New Jersey, New Brunswick

17033-0850

Penn State Milton S Hershey Medical Center, Hershey

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01727089 - Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer | Biotech Hunter | Biotech Hunter